News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
673,091 Results
Type
Article (57748)
Company Profile (222)
Press Release (615100)
Multimedia
Podcasts (198)
Webinars (30)
Section
Business (175739)
Career Advice (2527)
Deals (32386)
Drug Delivery (173)
Drug Development (82061)
Employer Resources (164)
FDA (17281)
Job Trends (13884)
News (316849)
Policy (34329)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2738)
Academic (1)
Accelerated approval (55)
Adcomms (40)
Allergies (180)
Alliances (46099)
ALS (226)
Alzheimer's disease (1959)
Antibody-drug conjugate (ADC) (540)
Approvals (17586)
Artificial intelligence (757)
Autoimmune disease (343)
Automation (54)
Bankruptcy (329)
Best Places to Work (10429)
BIOSECURE Act (23)
Biosimilars (235)
Biotechnology (151)
Bladder cancer (203)
Brain cancer (83)
Breast cancer (787)
Cancer (6226)
Cardiovascular disease (519)
Career advice (2156)
Career pathing (51)
CAR-T (338)
CDC (76)
Celiac Disease (3)
Cell therapy (955)
Cervical cancer (50)
Clinical research (71256)
Collaboration (2213)
Company closure (7)
Compensation (1441)
Complete response letters (105)
COVID-19 (2889)
CRISPR (121)
C-suite (1203)
Cystic fibrosis (162)
Data (8306)
Decentralized trials (3)
Denatured (61)
Depression (187)
Dermatology (92)
Diabetes (627)
Diagnostics (6373)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (43)
Drug discovery (388)
Drug pricing (245)
Drug shortages (39)
Duchenne muscular dystrophy (312)
Earnings (73002)
Editorial (78)
Employer branding (20)
Employer resources (145)
Events (102826)
Executive appointments (1101)
FDA (21203)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1765)
Gene editing (257)
Generative AI (68)
Gene therapy (798)
GLP-1 (1240)
Government (4678)
Grass and pollen (8)
Guidances (407)
Healthcare (17264)
HIV (87)
Huntington's disease (63)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (110)
Immunology and inflammation (347)
Immuno-oncology (109)
Indications (199)
Infectious disease (3252)
Inflammatory bowel disease (228)
Inflation Reduction Act (17)
Influenza (132)
Intellectual property (300)
Interviews (463)
IPO (15631)
IRA (61)
Job creations (3756)
Job search strategy (1758)
JPM (70)
Kidney cancer (22)
Labor market (105)
Layoffs (663)
Leadership (52)
Legal (8196)
Liver cancer (106)
Longevity (32)
Lung cancer (842)
Lymphoma (447)
Machine learning (63)
Management (55)
Manufacturing (1117)
MASH (218)
Medical device (12608)
Medtech (12731)
Mergers & acquisitions (18000)
Metabolic disorders (1704)
mRNA (247)
Multiple sclerosis (198)
NASH (24)
Neurodegenerative disease (490)
Neuropsychiatric disorders (124)
Neuroscience (3642)
Neurotech (2)
NextGen: Class of 2026 (5798)
Non-profit (4355)
Now hiring (53)
Obesity (831)
Opinion (365)
Ovarian cancer (221)
Pain (267)
Pancreatic cancer (331)
Parkinson's disease (406)
Partnered (29)
Patents (619)
Patient recruitment (702)
Peanut (66)
People (54392)
Pharmaceutical (47)
Pharmacy benefit managers (37)
Phase 1 (21933)
Phase 2 (31011)
Phase 3 (23836)
Pipeline (9264)
Policy (392)
Postmarket research (2925)
Preclinical (9389)
Press Release (61)
Prostate cancer (332)
Psychedelics (67)
Radiopharmaceuticals (356)
Rare diseases (1219)
Real estate (5319)
Recruiting (66)
Regulatory (27325)
Reports (49)
Research institute (2520)
Resumes & cover letters (412)
Rett syndrome (39)
RNA editing (25)
RSV (90)
Schizophrenia (193)
Series A (303)
Series B (215)
Service/supplier (11)
Sickle cell disease (122)
Special edition (30)
Spinal muscular atrophy (186)
Sponsored (53)
Startups (3474)
State (1)
Stomach cancer (21)
Supply chain (133)
Tariffs (104)
The Weekly (134)
Vaccines (1253)
Venture capital (128)
Weight loss (572)
Women's health (122)
Worklife (24)
Date
Today (161)
Last 7 days (749)
Last 30 days (3390)
Last 365 days (30678)
2026 (14347)
2025 (30670)
2024 (34707)
2023 (38970)
2022 (49766)
2021 (53526)
2020 (51061)
2019 (42158)
2018 (32105)
2017 (31977)
2016 (30678)
2015 (34507)
2014 (27586)
2013 (23027)
2012 (24681)
2011 (25421)
2010 (23665)
Location
Africa (866)
Alabama (90)
Alaska (6)
Arizona (295)
Arkansas (14)
Asia (41399)
Australia (7076)
California (13390)
Canada (3467)
China (1470)
Colorado (527)
Connecticut (614)
Delaware (426)
Europe (95716)
Florida (2026)
Georgia (418)
Hawaii (4)
Idaho (50)
Illinois (1047)
India (91)
Indiana (586)
Iowa (24)
Japan (564)
Kansas (127)
Kentucky (52)
Louisiana (41)
Maine (81)
Maryland (1627)
Massachusetts (9721)
Michigan (330)
Minnesota (713)
Mississippi (5)
Missouri (158)
Montana (29)
Nebraska (28)
Nevada (138)
New Hampshire (78)
New Jersey (3592)
New Mexico (31)
New York (3495)
North Carolina (1757)
North Dakota (9)
Northern California (6786)
Ohio (398)
Oklahoma (21)
Oregon (41)
Pennsylvania (2586)
Puerto Rico (30)
Rhode Island (46)
South America (1206)
South Carolina (86)
South Dakota (2)
Southern California (5272)
Tennessee (195)
Texas (2112)
United States (47177)
Utah (343)
Virginia (331)
Washington D.C. (78)
Washington State (1065)
West Virginia (4)
Wisconsin (139)
Wyoming (1)
673,091 Results for "alzheimer s drug discovery foundation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MindImmune Secures $5 Million Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Pioneer Immune-Driven Therapies for Alzheimer’s Disease
March 10, 2026
·
3 min read
Press Releases
Alzheimer’s Drug Discovery Foundation Appoints Isobel Coleman as Chief Executive Officer to Lead Next Era of Alzheimer’s Breakthroughs
March 11, 2026
·
3 min read
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity.
BioSpace
spoke to four industry executives about key issues facing those working in this space, starting with planning around uncertainty.
April 2, 2026
·
5 min read
·
Angela Gabriel
Approvals
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
May 1, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi. The new target action date is on Aug. 24.
May 8, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
February 11, 2026
·
8 min read
·
Annalee Armstrong
Alzheimer’s disease
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.
January 19, 2026
·
7 min read
·
Ben Hargreaves
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
·
1 min read
·
Heather McKenzie
Insights
AI Drug Discovery Platforms Face New Investor Bar
In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
March 17, 2026
·
3 min read
·
Jennifer C. Smith-Parker
1 of 67,310
Next
